On July 13, 2022 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that Company manufacturing leadership will present sessions on cutting edge topics in lipid-based nanoparticle delivery systems at the upcoming Next Generation Lipid-Based Nanoparticles Delivery Summit taking place from July 19-21, 2022 in Boston (Press release, Genprex, JUL 13, 2022, View Source [SID1234616706]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are extremely fortunate to have our critical manufacturing function led by Dr. Kumar and his talented team, including Dr. Shinde, and are pleased to see their well-deserved recognition as thought leaders in the rapidly evolving field of lipid nanoparticle delivery of therapeutics," said Rodney Varner, President and Chief Executive Officer of Genprex. "As we advance our lead development program in non-small cell lung cancer in Phase 1/2 clinical studies, it is more important than ever to have our gene therapy manufacturing in such capable hands and we are proud of our exceptional team."